Merck Fosamax Distribution Deal With CVS ProCare Draws Protest From NCPA
Executive Summary
The National Community Pharmacists Association is questioning the clinical necessity of limiting distribution of the 40 mg dose of Merck's Fosamax for Paget's disease to CVS ProCare.
You may also be interested in...
Medicare Rx Benefit Could Lead To Tightened Pediatric Exclusivity - CVS CEO
Congress will likely tighten the pediatric exclusivity incentive as it considers a Medicare drug benefit, CVS CEO Tom Ryan predicted during an earnings call.
Medicare Rx Benefit Could Lead To Tightened Pediatric Exclusivity - CVS CEO
Congress will likely tighten the pediatric exclusivity incentive as it considers a Medicare drug benefit, CVS CEO Tom Ryan predicted during an earnings call.
Merck Fosamax 40 mg Distribution Plan Leaves Room For Once-Weekly Agent
Merck's exclusive distribution program for patients receiving Fosamax 40 mg tablets for Paget's disease will give the company pricing flexibility when a once-weekly 35 mg formulation is approved for prevention of osteoporosis.